RCKT - Rocket Pharmaceuticals, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.42
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.00
DETAILS
HIGH:
$7.00
LOW:
$5.00
MEDIAN:
$6.00
CONSENSUS:
$6.00
UPSIDE:
41.18%
Market Cap:
459.94M
Volume:
3,033,550
Avg Volume:
2,026,495
52 Week Range:
2.19-10.62
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.47
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
299
IPO Date:
2015-02-18
EPS (TTM):
-2.73
P/E Ratio:
-4.61
Revenue (TTM):
N/A
Total Assets:
527.70M
Total Debt:
25.50M
Cash & Equiv:
163.63M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-52.7%
Debt/Equity:
0.06
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-0.45 | $-0.48 | +6.2% | — | $312500 | — |
| 2025-08-07 | $-0.59 | $-0.57 | -3.5% | — | $4.4M | — |
| 2025-05-08 | $-0.56 | $-0.59 | +5.1% | — | $800000 | — |
| 2025-02-27 | $-0.62 | $-0.68 | +8.8% | — | $28455 | — |
| 2024-11-07 | $-0.71 | $-0.78 | +9.0% | — | $34780 | — |
| 2024-08-05 | $-0.74 | $-0.74 | 0.0% | — | — | — |
| 2024-05-06 | $-0.66 | $-0.69 | +4.3% | — | $110000 | — |
| 2024-02-26 | $-0.64 | $-0.80 | +20.0% | $10.3M | — | — |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (258.75M) | (245.59M) | (221.86M) | (169.07M) | (146.67M) | (83.23M) | (74.52M) | (29.50M) | (42.85M) | (67.98M) | (9.53M) | (7.62M) |
| EPS | -2.73 | -2.92 | -3.26 | -2.68 | -2.52 | -1.70 | -1.89 | -4.36 | -6.41 | -10.29 | -4.53 | -3.62 |
| Total Assets | 527.70M | 566.34M | 551.81M | 497.02M | 590.82M | 372.12M | 251.31M | 101.78M | 129.65M | 113.32M | 5.52M | 12.86M |
| Total Debt | 25.50M | 25.04M | 22.87M | 22.60M | 61.70M | 47.45M | 41.45M | 49.54M | 48.96M | 0 | 7.15M | 6.80M |
| Cash & Equivalents | 163.63M | 55.90M | 140.52M | 232.69M | 297.10M | 185.38M | 111.36M | 78.72M | 29.80M | 80.04M | 3.62M | 12.79M |
| Operating Cash Flow | (209.72M) | (194.92M) | (178.14M) | (121.16M) | (74.64M) | (64.66M) | (53.79M) | (26.11M) | (37.27M) | (17.42M) | (9.74M) | (6.46M) |
| Free Cash Flow | (215.59M) | (211.39M) | (186.76M) | (128.88M) | (103.70M) | (87.93M) | (55.24M) | (26.18M) | (37.75M) | (17.83M) | (9.74M) | (6.46M) |
| FCF per Share | -2.27 | -2.52 | -2.74 | -2.04 | -1.87 | -1.79 | -1.40 | -3.87 | -5.65 | -2.70 | -4.63 | -3.07 |
| Book Value | 463.23M | 492.57M | 489.69M | 454.72M | 503.52M | 307.30M | 194.04M | 47.76M | 73.17M | 108.81M | (51.56M) | (38.90M) |
| Cash & ST Investments | 372.34M | 373.18M | 356.39M | 388.74M | 482.72M | 304.12M | 205.73M | 100.01M | 126.47M | 111.28M | 3.62M | 12.79M |
| ROC Equity | -0.56 | -0.50 | -0.45 | -0.37 | -0.29 | -0.27 | -0.38 | -0.62 | -0.59 | -0.62 | N/A | N/A |